ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

ENHERTU AND YOU

A treatment option for previously treated people with HER2-positive (IHC 3+) metastatic tumors who have no other treatment options

Not actual patients.

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

- ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

It is not known if ENHERTU is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

- **Lung problems that may be severe, life-threatening or that may lead to death.** If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms: ◦ Cough ◦ Trouble breathing or shortness of breath ◦ Fever ◦ Other new or worsening breathing symptoms (such as chest tightness, wheezing)

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Your guide to ENHERTU

Whether you have already started on or are considering treatment with ENHERTU, this brochure is designed to provide you with:

- Information about ENHERTU and HER2 positivity
- Clinical trial results
- Possible side effects, including serious ones
- Details about how you will receive ENHERTU
- Financial support options

It may be helpful for you to review this brochure with your healthcare team, who can answer any further questions you may have.

Use the tabs at the right of this brochure to find information about your specific type of cancer.

Important Safety Information (cont'd)

- **Low white blood cell count (neutropenia).** Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

What should I know about HER2 and HER2 positivity?

HER2 is a protein that tells cells to grow. When cells produce too much HER2, they can become cancerous.

Excessive amounts of HER2 can be found in many different tumors.

HER2 levels can be determined by a testing method called immunohistochemistry (IHC).

HER2 IHC scores range from IHC 0 to IHC 3+. The highest level of HER2 positivity is IHC 3+.

ENHERTU is approved to treat certain patients who have HER2-positive (HER2+) cancers with a HER2 IHC score of 3+. Your score helps your healthcare provider determine if you may be eligible for ENHERTU.

Important Safety Information (cont'd)

- **Heart problems that may affect your heart's ability to pump blood.** Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms: ◦ New or worsening shortness of breath ◦ Coughing ◦ Feeling tired ◦ Swelling of your ankles or legs ◦ Irregular heartbeat ◦ Sudden weight gain ◦ Dizziness or feeling light-headed ◦ Loss of consciousness

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

The highest level of HER2 positivity (IHC 3+) occurs in many different types of solid tumors,* including:

Biliary Tract	**Ovarian**	**Salivary Gland**
Cervical	**Endometrial**	**Lung** (non-small cell)
Pancreatic	**Bladder**	**Colorectal**

The highest level of HER2 positivity (IHC 3+) also occurs in multiple other tumor types.

Learn more about ENHERTU for the treatment of certain patients with HER2+ (IHC 3+) metastatic tumors at ENHERTU.com/IHC3plus-tumors

*A solid tumor is a mass of cancer cells that grows in organs, muscles, or bones.

Important Safety Information (cont'd)

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

ENHERTU was studied in 3 clinical trials of many different types of metastatic solid tumors that had the highest level of HER2 positivity (IHC 3+)

These 3 clinical trials included 192 previously treated adults:

- **111 people** with various types of metastatic tumors, including biliary tract, pancreatic, ovarian, cervical, endometrial, bladder, salivary gland, and other cancers
- **17 people** with metastatic non-small cell lung cancer (mNSCLC)
- **64 people** with metastatic colorectal cancer (mCRC)

These studies only evaluated ENHERTU. There were no comparisons of results to other treatment options. Individual results may vary. ENHERTU may not work for everyone.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

Important Safety Information (cont'd)

- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.
  - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
  - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose.
  - **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

In the 3 clinical trials,

About half of people treated with ENHERTU had their tumors shrink*

*This is called the overall response rate.

In people with various metastatic tumors,	In people with mNSCLC,	In people with mCRC,
51.4% (57 of 111 people) had their tumors shrink*	**52.9%** (9 of 17 people) had their tumors shrink*	**46.9%** (30 of 64 people) had their tumors shrink*
• **2.7%** (3 people) had a complete response†	• **5.9%** (1 person) had a complete response†	• 0 people had a complete response†
• **48.6%** (54 people) had a partial response‡	• **47.1%** (8 people) had a partial response‡	• **46.9%** (30 people) had a partial response‡
• Median duration of response: **19.4** (range: 1.3 to 27.9+) months§	• Median duration of response: **6.9** (range: 4.0 to 11.7+) months§	• Median duration of response: **5.5** (range: 1.3+ to 9.7+) months§

A median is the middle number in a set of numbers.
+ indicates that the response to treatment is ongoing.

†**Complete response** means there are no signs of cancer on a follow-up scan.
‡**Partial response** means the tumors shrank by at least 30%.
§**Median duration of response** is the length of time half of the people who responded to ENHERTU continued to respond after the first response was seen.

Important Safety Information (cont'd)

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

- Have lung or breathing problems.
- Have signs or symptoms of an infection.
- Have or have had any heart problems.
- Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Results in lung cancer

These pages are limited to ENHERTU data in previously treated patients with lung cancer that is HER2 positive (IHC 3+) only; these data do not address all lung cancer clinical trial data for ENHERTU.

In the clinical trial of 17 people with previously treated HER2+ (IHC 3+) metastatic non-small cell lung cancer (mNSCLC),

About 50% of people treated with ENHERTU had their tumors shrink

This is called the overall response rate.

- 52.9% (9 of 17 people) had an overall response, 5.9% (1 person) had no signs of their cancer on a follow-up scan (complete response), and 47.1% (8 people) had their tumors shrink by at least 30% (partial response)

Important Safety Information (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ENHERTU?

- You will receive ENHERTU into your vein through an intravenous (IV line by your healthcare provider.
- ENHERTU is given 1 time every three weeks (21-day treatment cycle).
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.
- Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
- If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

50% of people who responded to ENHERTU were responding after



This is called median duration of response.*

+ indicates that the response to treatment is ongoing.

*A median is the middle number in a set of numbers. Median duration of response is the length of time half of the people who responded to ENHERTU continued to respond after the first response was seen.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

Important Safety Information (cont'd)

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See "What is the most important information I should know about ENHERTU?"

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Results in colorectal cancer

In the clinical trial of 64 people with previously treated HER2+ (IHC 3+) metastatic colorectal cancer (mCRC),

Nearly 50% of people treated with ENHERTU had their tumors shrink

This is called the overall response rate.

- 46.9% (30 of 64 people) had an overall response, 0% had no signs of their cancer on a follow-up scan (complete response), and 46.9% (30 people) had their tumors shrink by at least 30% (partial response)

Important Safety Information (cont'd)

The most common side effects of ENHERTU when used at the 5.4 mg/kg dose include:

- Low white blood cell counts
- Nausea
- Low red blood cell counts
- Feeling tired
- Low platelet counts
- Increased liver function tests
- Vomiting
- Hair loss
- Constipation
- Low levels of blood potassium
- Decreased appetite
- Diarrhea
- Muscle or bone pain

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

50% of people who responded to ENHERTU were responding after



This is called median duration of response.*

+ indicates that the response to treatment is ongoing.

*A median is the middle number in a set of numbers. Median duration of response is the length of time half of the people who responded to ENHERTU continued to respond after the first response was seen.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

Important Safety Information (cont'd)

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Outcomes in selected tumor types in the clinical trial of 111 people with various previously treated HER2+ (IHC 3+) metastatic cancers*

Results in other digestive system (gastrointestinal) cancers

Results with ENHERTU in people with cancers of the digestive system (gastrointestinal)

Biliary tract (22 people)

Overall response rate



Duration of response (range)†

People who responded to ENHERTU responded for a range of

+ indicates that the response to treatment is ongoing.

*Tumor types included biliary tract [22 people], pancreatic [5 people], ovarian [15 people], cervical [10 people], endometrial [16 people], bladder [27 people], and other cancers [16 people].
†Duration of response is the length of time the people who responded to ENHERTU continued to respond after the first response was seen.

Important Safety Information (cont'd)

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Results in other digestive system (gastrointestinal) cancers (cont'd)

Pancreatic (5 people)

Overall response rate



ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

Important Safety Information (cont'd)

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

- ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

It is not known if ENHERTU is safe and effective in children.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Outcomes in selected tumor types in the clinical trial of 111 people with various previously treated HER2+ (IHC 3+) metastatic cancers*

Results in gynecologic cancers

Results with ENHERTU in people with ovarian and cervical cancers

Ovarian (15 people)

Overall response rate	Duration of response (range)†
66.7% (10 of 15 people) had their tumors shrink	People who responded to ENHERTU responded for a range of 1.3 to 27.9+ months

+ indicates that the response to treatment is ongoing.

*Tumor types included biliary tract [22 people], pancreatic [5 people], ovarian [15 people], cervical [10 people], endometrial [16 people], bladder [27 people], and other cancers [16 people].
†Duration of response is the length of time the people who responded to ENHERTU continued to respond after the first response was seen.

Important Safety Information (cont'd)

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

- **Lung problems that may be severe, life-threatening or that may lead to death.** If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms: ◦ Cough ◦ Trouble breathing or shortness of breath ◦ Fever ◦ Other new or worsening breathing symptoms (such as chest tightness, wheezing)

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Results in gynecologic cancers (cont'd)

Cervical (10 people)

Overall response rate	Duration of response (range)†
70.0% (7 of 10 people) had their tumors shrink	People who responded to ENHERTU responded for a range of 7.2+ to 25.0+ months

+ indicates that the response to treatment is ongoing.

†Duration of response is the length of time the people who responded to ENHERTU continued to respond after the first response was seen.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

Important Safety Information (cont'd)

- **Low white blood cell count (neutropenia).** Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Outcomes in selected tumor types in the clinical trial of 111 people with various previously treated HER2+ (IHC 3+) metastatic cancers*

Results in gynecologic cancers (cont'd)

Results with ENHERTU in people with endometrial cancer

Endometrial (16 people)

Overall response rate



Duration of response (range)†

People who responded to ENHERTU responded for a range of

+ indicates that the response to treatment is ongoing.

*Tumor types included biliary tract [22 people], pancreatic [5 people], ovarian [15 people], cervical [10 people], endometrial [16 people], bladder [27 people], and other cancers [16 people].
†Duration of response is the length of time the people who responded to ENHERTU continued to respond after the first response was seen.

Important Safety Information (cont'd)

- **Heart problems that may affect your heart's ability to pump blood.** Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms: ◦ New or worsening shortness of breath ◦ Coughing ◦ Feeling tired ◦ Swelling of your ankles or legs ◦ Irregular heartbeat ◦ Sudden weight gain ◦ Dizziness or feeling light-headed ◦ Loss of consciousness

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Outcomes in selected tumor types in the clinical trial of 111 people with various previously treated HER2+ (IHC 3+) metastatic cancers*

Results in bladder cancer

Results with ENHERTU in people with bladder cancer

Bladder (27 people)

Overall response rate



Duration of response (range)†

People who responded to ENHERTU responded for a range of

+ indicates that the response to treatment is ongoing.

*Tumor types included biliary tract [22 people], pancreatic [5 people], ovarian [15 people], cervical [10 people], endometrial [16 people], bladder [27 people], and other cancers [16 people].
†Duration of response is the length of time the people who responded to ENHERTU continued to respond after the first response was seen.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

Important Safety Information (cont'd)

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Outcomes in selected tumor types in the clinical trial of 111 people with various previously treated HER2+ (IHC 3+) metastatic cancers*

Results in additional cancers

Results with ENHERTU in people with salivary gland cancer†

Salivary gland (9 people)

Overall response rate	Duration of response (range)‡
66.7% (6 of 9 people) had their tumors shrink	People who responded to ENHERTU responded for a range of 5.6 to 20.1 months

*Tumor types included biliary tract [22 people], pancreatic [5 people], ovarian [15 people], cervical [10 people], endometrial [16 people], bladder [27 people], and other cancers [16 people].
†The tumors studied in the group of 16 people with other cancers included salivary gland [9 people]; mouth and throat (oropharyngeal) [1 person]; vulvar [1 person]; skin cancer affecting the sweat glands [1 person]; tear gland [1 person]; lip/oral [1 person]; esophageal [1 person]; and esophageal (squamous cell) [1 person].
‡Duration of response is the length of time the people who responded to ENHERTU continued to respond after the first response was seen.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

Important Safety Information (cont'd)

- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.
  - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
  - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose.
  - **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.



Not actual patients.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

During treatment with ENHERTU, side effects may occur and you should notify your healthcare provider as early as possible

ENHERTU can cause serious, potentially fatal side effects. See pages 22-23 for the most important information you should know about ENHERTU.

The most common side effects of ENHERTU when used at the 5.4 mg/kg dose include:

- Low white blood cell counts
- Nausea
- Low red blood cell counts
- Feeling tired
- Low platelet counts
- Increased liver function tests
- Vomiting
- Hair loss
- Constipation
- Low levels of blood potassium
- Decreased appetite
- Diarrhea
- Muscle or bone pain

- The majority of side effects in people receiving ENHERTU were mild or moderate;* however, some people may have serious side effects that could lead to death. It is important to call your doctor for medical advice about side effects

*Mild side effects are side effects you may have but they show no outward signs or medical intervention may not be needed. Moderate side effects may require some medical intervention or may affect you as you do day-to-day activities.

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU.

Call your doctor for medical advice about side effects.

You are encouraged to report side effects of ENHERTU by calling 1-877-437-7763. If you prefer to report these to the FDA, visit www.FDA.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Please see Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Will my healthcare provider adjust my dose if I have side effects?

Your healthcare provider may modify your dose to help you manage side effects. It is important to call your healthcare provider right away for medical advice.

To help manage side effects, your healthcare provider may:

Delay your dose | **Reduce your dose** | **Stop ENHERTU**

Your healthcare provider should give you medicine to help with nausea and vomiting before your infusion. See pages 24-25 for helpful tips on managing side effects.

Find details about how you will receive ENHERTU on pages 28 and 32 of this brochure.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects. Some serious or life-threatening side effects may affect your lungs, heart, or white blood cell count, affecting your ability to fight infection.

Pay special attention to new or worsening symptoms, as they may be related to:

Lung problems, like interstitial lung disease/ pneumonitis, that may be severe, life-threatening, or that may lead to death

Call or see your healthcare provider right away if you develop any of the following signs and symptoms or if these symptoms get worse:

- Cough
- Trouble breathing or shortness of breath
- Fever
- Other new or worsening breathing symptoms (such as chest tightness, wheezing)

If lung problems develop your healthcare provider may treat you with corticosteroid medicines.

Low white blood cell count (neutropenia)

- Low white blood cell counts are common with ENHERTU and can sometimes be severe
- Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose
- Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU

Please see Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Heart problems that may affect your heart's ability to pump blood

Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:

- New or worsening shortness of breath
- Coughing
- Feeling tired
- Swelling of your ankles or legs
- Irregular heartbeat
- Sudden weight gain
- Dizziness or feeling light-headed
- Loss of consciousness

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment, or completely stop treatment with ENHERTU if you have severe side effects.

Harm to your unborn baby

Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.

- If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU
- **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose
- **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Useful tips that may help you manage some of these side effects

The tips below are not intended to take the place of your healthcare team's advice. Always talk to your healthcare provider first.

For nausea and vomiting

Your healthcare provider should give you medicine to help with nausea and vomiting before your infusion. Talk to your doctor immediately if you did not receive these medications or if you continue to experience nausea and vomiting with your current medicine. These tips may help:

- Try to eat 5 or 6 small meals and snacks each day instead of 3 large meals
- Eat bland, easy-to-digest food and drinks
- Avoid food and drinks that are too hot or too cold
- Avoid strong smells if possible
- If you feel like vomiting, take deep, slow breaths and, if possible, get fresh air

For diarrhea

- Try to eat 5 or 6 small meals and snacks each day instead of 3 large meals
- Eat foods low in fiber
- Drink clear liquids to replace lost fluids. Check with your healthcare provider to figure out how much and what types of fluid might be best

For tiredness or fatigue

- Drink plenty of fluids each day. Ask your doctor what types of liquids are appropriate for you
- Try activities such as meditation, which helps with relaxation and decreases stress
- Plan rest time and try not to do too much
- Try regular exercise during times when your energy level is high (according to your healthcare provider's approval)
- If possible, let other people help you with everyday tasks, such as household chores, shopping, cooking, or driving to and from doctor's visits

For dealing with hair thinning or hair loss (alopecia)

- Talk to your healthcare provider about the possibility of hair thinning or hair loss
- Consider cutting your hair short to feel more in control of hair loss and be gentle when washing your hair. Use a mild shampoo
- Avoid electric hair dryers, products to perm or relax hair, hair bands, and/or clips that can hurt your scalp
- Consider asking your healthcare provider about cold caps or scalp cooling systems, which may help reduce hair loss by narrowing the blood vessels beneath your scalp
- Protect your scalp by wearing a hat or head covering, applying sunscreen, and avoiding very hot or cold places
- Sleep on a satin pillowcase. Satin creates less friction and may be more comfortable

Please see Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

What to tell your healthcare provider

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

- Have lung or breathing problems
- Have kidney problems. Your healthcare provider may follow you more closely. In clinical trials, more serious lung problems were seen in patients with certain kidney problems
- Have liver problems. Your healthcare provider may follow you more closely.
- Have signs or symptoms of an infection
- Have or have had any heart problems
- Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Remember to call your healthcare provider right away for medical advice if you experience any side effects.

It is important to manage any side effects you may have with your healthcare provider.

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

How is ENHERTU thought to work?

As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies.



ENHERTU is made up of an antibody with the chemotherapy attached



The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell



ENHERTU enters the cancer cell and the chemotherapy is released



The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby

Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells.

ENHERTU may not work for everyone.

Important Safety Information (cont'd)

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

- Have lung or breathing problems.
- Have signs or symptoms of an infection.
- Have or have had any heart problems.
- Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

How will I receive ENHERTU?

ENHERTU is given as an intravenous (IV) infusion. You will receive an ENHERTU infusion once every 3 weeks, either at your oncologist's office or at a nearby infusion center.

Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting

The first ENHERTU infusion will take about 90 minutes so the healthcare provider can monitor any potential reactions

Future ENHERTU infusions should take about 30 minutes, if your first infusion was well tolerated

If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

Important Safety Information (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Not an actual patient.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Important Safety Information

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

- **Lung problems that may be severe, life-threatening or that may lead to death.** If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  - Cough
  - Trouble breathing or shortness of breath
  - Fever
  - Other new or worsening breathing symptoms (such as chest tightness, wheezing)

- **Low white blood cell count (neutropenia).** Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

- **Heart problems that may affect your heart's ability to pump blood.** Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  - New or worsening shortness of breath
  - Coughing
  - Feeling tired
  - Swelling of your ankles or legs
  - Irregular heartbeat
  - Sudden weight gain
  - Dizziness or feeling light-headed
  - Loss of consciousness

Please see additional Important Safety Information on pages 32-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.
  - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
  - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose.
  - **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

- Have lung or breathing problems.
- Have signs or symptoms of an infection.
- Have or have had any heart problems.
- Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Continued on next page

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Important Safety Information (cont'd)

How will I receive ENHERTU?

- You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider.
- ENHERTU is given 1 time every three weeks (21-day treatment cycle).
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.
- Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
- If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See "What is the most important information I should know about ENHERTU?"

The most common side effects of ENHERTU when used at the 5.4 mg/kg dose include:

- Low white blood cell counts
- Nausea
- Low red blood cell counts
- Feeling tired
- Low platelet counts
- Increased liver function tests
- Vomiting
- Hair loss
- Constipation
- Low levels of blood potassium
- Decreased appetite
- Diarrhea
- Muscle or bone pain

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information on pages 30-31 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

- ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

It is not known if ENHERTU is safe and effective in children.

Please see accompanying full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Get support that stands with you

ENHERTU4U may be able to help you access and afford treatment with ENHERTU after it has been prescribed

The ENHERTU4U program is designed to help you access and afford your prescribed ENHERTU treatment, including benefits reviews, prior authorization and/or claims appeal information, and paying for your prescription.

Access

ENHERTU4U is here to help your healthcare provider understand your insurance company's requirements for access to treatment with ENHERTU.

Financial Assistance

We have multiple options to help you afford your treatment. Your healthcare provider can provide more information about how **ENHERTU4U** may be able to help.

For support from ENHERTU4U, please call 1-833-ENHERTU (1-833-364-3788) or visit ENHERTU4U.com

ENHERTU4U does not guarantee access or cost savings for patients prescribed ENHERTU.

Please see Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Connect with helpful resources

American Cancer Society
www.cancer.org

CancerCare®
www.cancercare.org

Cancer Support Community
www.cancersupportcommunity.org

This is not an all-inclusive list of resources.

For information about your ENHERTU treatment, visit ENHERTU.com/IHC3plus-tumors

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Find out more about ENHERTU
Talk to your healthcare provider and visit ENHERTU.com/IHC3plus-tumors

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

- ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

It is not known if ENHERTU is safe and effective in children.

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.

SELECT IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

- **Lung problems that may be severe, life-threatening or that may lead to death.** If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms: ◦ Cough ◦ Trouble breathing or shortness of breath ◦ Fever ◦ Other new or worsening breathing symptoms (such as chest tightness, wheezing)

If you are interested in sharing your story and experience with HER2+ (IHC 3+) metastatic tumors, please call 1-877-4DS-PROD (1-877-437-7763) or email DSAdvocacy@dsi.com to speak with a Daiichi Sankyo and/or AstraZeneca representative.

References: 1. ENHERTU. Prescribing information. Daiichi Sankyo, Inc.; 2025. **2.** National Cancer Institute. NCI dictionary of cancer terms. Accessed January 18, 2024. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/her2 **3.** Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial. *J Clin Oncol.* 2023:JCO2302005 **4.** Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. *J Clin Oncol.* 2020;38(17):1951-1962. **5.** National Institutes of Health. Childhood cancer and functional impacts across the care continuum. Accessed February 7, 2024. https://www.ncbi.nlm.nih.gov/books/NBK569407 **6.** National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Published November 27, 2017. **7.** National Cancer Institute. Chemotherapy and you. Accessed January 18, 2024. https://www.cancer.gov/publications/patient-education/chemotherapy-and-you.pdf **8.** American Cancer Society. Cooling caps (scalp hypothermia) to reduce hair loss. Accessed January 18, 2024. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/hair-skin-nails/hair-loss/cold-caps.html **9.** Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. *Clin Cancer Res.* 2016;22(20):5097-5108. **10.** Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. *Chem Pharm Bull (Tokyo).* 2019;67(3):173-185.

Please see additional Important Safety Information on pages 30-33 of this brochure, and click here for full ENHERTU Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Daiichi-Sankyo | AstraZeneca